Inceptor Bio to Present at AACR 2025: Spotlight on IB-T101 and the OUTLAST™ Platform April 22, 2025 Read More »
Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing February 25, 2025 Read More »
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform December 18, 2024 Read More »
Inceptor Bio to Present at the BioCentury Inc. East-West Summit in Boston October 3, 2023 Read More »
